Viatris Inc. (VTRS)
Free
No email, no account, no signup.
Pulling latest news for Viatris Inc.…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Global healthcare and pharmaceuticals
Market Cap
$17.5B
Market sentiment
Sentiment has improved materially following the Q1 beat and reaffirmed guidance, supported by strong price/volume momentum and a more constructive narrative around Greater China growth and capital deployment.
Why BUY ?
The revenue/earnings beat plus reaffirmed full-year guidance increases confidence in meeting 2026 targets. The price/volume reaction suggests improving market perception, and nearer-term catalysts (July PDUFA) could support further re-rating, though execution and restructuring risks remain.
- ADD in a small size or scale in (e.g., 1/3 now, 1/3 on pullback, 1/3 into the PDUFA), with clear risk controls given the stock is near its 52-week high.
We're already tracking Viatris Inc. — here are the latest events we've registered
Recent News
- On May 7, 2026, Viatris reported Q1 2026 results with revenue of $3.517B (+8% YoY), GAAP net income of $176M, and adjusted EPS of $0.59 (above consensus). The company reaffirmed full-year 2026 guidance and the stock rose ~9% on sharply higher volume. CFO Doretta Mistras is departing (staying through May 22) with Paul Campbell as interim CFO. Investors are also focusing on stronger Greater China performance (e-commerce) and upcoming regulatory/clinical milestones.
Want to know how this news affects Viatris Inc.? Order the analysis.
Order analysis – Catalysts
30 Jul 2026 — Xulane LO: PDUFA decision on July 30, 2026
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Viatris Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.